<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Xenon Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc</link>
<description>Latest news and press releases for Xenon Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 19 Apr 2026 22:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/xenon-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835db6678dffbe2df123dd2.webp</url>
<title>Xenon Pharmaceuticals Inc</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc</link>
</image>
<item>
<title>Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-presents-azetukalner-phase-3-x-tole2-study-results-and-48-month-long-term-data-in-focal-onset-seizures-at-2026-aan-annual-meeting</guid>
<pubDate>Sun, 19 Apr 2026 22:00:00 GMT</pubDate>
<description>Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind periodLong-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in</description>
</item>
<item>
<title>Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-to-highlight-phase-3-x-tole2-and-long-term-data-for-azetukalner-in-focal-onset-seizures-at-2026-aan-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-to-highlight-phase-3-x-tole2-and-long-term-data-for-azetukalner-in-focal-onset-seizures-at-2026-aan-annual-meeting</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures</description>
</item>
<item>
<title>Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-announces-closing-of-dollar7475-million-upsized-public-offering-including-full-exercise-of-the-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-announces-closing-of-dollar7475-million-upsized-public-offering-including-full-exercise-of-the-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Thu, 12 Mar 2026 20:01:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the closing of its previously announced underwritten public offering of 12,236,843 common shares, which includes 1,710,526 shares sold upon the full exercise of the underwriters’ option to</description>
</item>
<item>
<title>Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-announces-pricing-of-upsized-dollar6500-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-announces-pricing-of-upsized-dollar6500-million-public-offering</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-positive-topline-data-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-fos</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-positive-topline-data-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-fos</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg dose compared</description>
</item>
<item>
<title>Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-to-announce-topline-results-from-phase-3-x-tole2-study-of-azetukalner-in-focal-onset-seizures-on-monday-march-9-2026</guid>
<pubDate>Sun, 08 Mar 2026 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-reports-q4-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-reports-q4-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in</description>
</item>
<item>
<title>Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-reports-inducement-grants-210500896</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-pharmaceuticals-reports-inducement-grants-210500896</guid>
<pubDate>Fri, 16 Jan 2026 21:05:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of t</description>
</item>
<item>
<title>Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-outlines-key-upcoming-milestones-133000049</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-outlines-key-upcoming-milestones-133000049</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3 X-NOVA2 topline data in MDD expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain VANCOUVER, British Columbia and BOSTON</description>
</item>
<item>
<title>Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-showcases-new-48-month-azetukalner-ole-study-data-epilepsy-aes-2025-2025-12-05</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-showcases-new-48-month-azetukalner-ole-study-data-epilepsy-aes-2025-2025-12-05</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure freedomNew X-TOLE</description>
</item>
<item>
<title>Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-investor-webinar-highlighting-azetukalner-and-epilepsy-data-aes-2025</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-investor-webinar-highlighting-azetukalner-and-epilepsy-data-aes-2025</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-present-new-azetukalner-ole-study-data-epilepsy-aes-2025-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-present-new-azetukalner-ole-study-data-epilepsy-aes-2025-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term</description>
</item>
<item>
<title>Xenon to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-present-upcoming-investor-conferences-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-present-upcoming-investor-conferences-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Xenon Reports Third Quarter 2025 Financial Results & Business Update</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-reports-third-quarter-2025-financial-results-business-update-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-reports-third-quarter-2025-financial-results-business-update-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3</description>
</item>
<item>
<title>Xenon to Report Q3 2025 Financial Results on November 3, 2025</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-report-q3-2025-financial-results-november-3-2025-2025-10-27</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-report-q3-2025-financial-results-november-3-2025-2025-10-27</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-appointment-tucker-kelly-chief-financial-officer-2025-10-16</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-appointment-tucker-kelly-chief-financial-officer-2025-10-16</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience VANCOUVER, British Columbia and</description>
</item>
<item>
<title>Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-upcoming-investor-webinar-discuss-early-stage-ion-channel-programs</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-announces-upcoming-investor-webinar-discuss-early-stage-ion-channel-programs</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical</description>
</item>
<item>
<title>Design Therapeutics Appoints Justin Gover to Board of Directors</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/design-therapeutics-appoints-justin-gover-to-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/design-therapeutics-appoints-justin-gover-to-board-of-directors-1</guid>
<pubDate>Wed, 10 Sep 2025 20:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company</description>
</item>
<item>
<title>Xenon Reports Second Quarter 2025 Financial Results & Business Update</title>
<link>https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-reports-second-quarter-2025-financial-results-business-update-2025-08-11</link>
<guid isPermaLink="true">https://6ix.com/company/xenon-pharmaceuticals-inc/news/xenon-reports-second-quarter-2025-financial-results-business-update-2025-08-11</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric</description>
</item>
</channel>
</rss>